ASSESSMENT OF GENOTOXICITY OF VINCRISTINE, VINBLASTINE AND VINORELBINE IN HUMAN CULTURED LYMPHOCYTES: A COMPARATIVE STUDY
Mhaidat NM, Alzoubi KH, Khabour OF, Alawneh KZ, Raffee LA, Alsatari ES, Hussein EI, Bani-Hani KE
*Corresponding Author: Nizar M. Mhaidat, Ph.D., Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Amman-Ramtha Hwy, Irbid 22110, Jordan. Tel: +962- 2-720-100. Fax: +962-2-720-1075. E-mail: nizarm@just.edu.jo
page: 13

REFERENCES

1. Facchini PJ, De Luca V. Opium poppy and Madagascar periwinkle: Model non-model systems to investigate alkaloid biosynthesis in plants. Plant J. 2008; 54(4): 763-784. 2. Moudi MR, Go R, Yien CY, Nazre M. Vinca alkaloids. Int J Prev Med. 2013; 4(11): 1231-1235. 3. Duffin J. Poisoning the spindle: Serendipity and discovery of the anti-tumor properties of the Vinca alkaloids. Pharm Hist. 2002; 44(2?): 64-76. 4. Ribatti D, Guidolin D, Conconi MT, Nico B, Baiguera S, Parnigotto PP, et al. Vinblastine inhibits the angiogenic response induced by adrenomedullin in vitro and in vivo. Oncogene. 2003; 22(41): 6458-6461. 5. Toussaint C, Izzo J, Spielmann M, Merle S, May- Levin F, Armand JP, et al. Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer. J Clin Oncol. 1994; 12(10): 2102-2112. 6. Freyer G, Delozier T, Lichinister M, Gedouin D, Bougnoux P, His P, et al. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol. 2003; 21(1): 35-40. 7. Rusthoven J, Bramwell V, Stephenson B. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group. Cancer Prev Control. 1998; 2(4): 179-190. 8. Hirano M, Okamoto M, Maruyama F, Ezaki K, Shimizu K, Ino T, et al. Alternating non-crossresistant chemotherapy for non-Hodgkin’s lymphoma of inter-mediate-grade and high-grade malignancy. A pilot study. Cancer. 1992; 69(3): 772-777. 9. Coderch C, Morreale A, Gago F. Tubulin-based structure-affinity relationships for antimitotic Vinca alkaloids. Anticancer Agents Med Chem. 2012; 12(3): 219-225. 10. Jiang W, Lu Y, Chen Z, Chen S, Zhang M, Jin L, et al. Studying the genotoxicity of vincristine on human lymphocytes using comet assay, micronucleus assay and TCR gene mutation test in vitro. Toxicology. 2008; 252(1-3): 113-117. 11. Choudhury RC, Palo AK, Padhy A. Cytogenetic consequences of vinblastine treatment in mouse bone marrow. Chemotherapy. 2004; 50(4): 171-177. 12. Morales-Ramirez P, Vallarino-Kelly T, Cruz- Vallejo V. Kinetics of micronucleus induction and cytotoxicity caused by distinct antineoplastics and alkylating agents in vivo. Toxicol Lett. 2014; 224(3): 319-325. 13. Morales-Ramirez P, Vallarino-Kelly T, Cruz- Vallejo V. Kinetics of micronucleated polychromatic erythrocyte (MN-PCE) induction in vivo by aneuploidogens. Mutat Res. 2004; 565(1): 79-87. 14. Yamada T, Odawara K, Kaneko H. Concurrent detection of gene mutations and chromosome aberrations induced by five chemicals in a CHL/ IU cell line incorporating a gpt shuttle vector. Mutat Res. 2000; 471(1-2): 29-36. 15. Arni P, Hertner T. Chromosomal aberrations in vitro induced by aneugens. Mutat Res. 1997; 379(1): 83-93. 16. Gonzalez-Cid M, Larripa I, Slavutsky I. Vinorelbine: Cell cycle kinetics and differential sensitivity of human lymphocyte subpopulations. Toxicol Lett. 1997; 93(2-3): 171-176. 17. Tiburi M, Reguly ML, Schwartsmann G, Cunha KS, Lehmann M, Rodrigues de Andrade HH. Comparative genotoxic effect of vincristine, vinblastine, and vinorelbine in somatic cells of Drosophila melanogaster. Mutat Res. 2002; 519(1-2): 141-149. 18. Gundy S, Baki M, Bodrogi I. Vinblastine, cisplatin and bleomycin (VPB) adjuvant therapy does not induce dose-dependent damage in human chromosomes. Neoplasma. 1989; 36(4): 457-464. 19. Morgan WF, Crossen PE. A comparison of induced sister chromatid exchange levels in Chinese hamster ovary cells and cultured human lymphocytes. Environ Mutagen. 1982; 4(1): 65-71. 20. Gonzalez-Cid M, Cuello MT, Larripa I. Mitotic arrest and anaphase aberrations induced by vinorelbine in hamster cells in vitro. Anticancer Drugs. 1997; 8(5): 529-532. 21. Alzoubi K, Khabour O, Khader M, Mhaidat N, Al-Azzam S. Evaluation of vitamin B12 effects on DNA damage induced by paclitaxel. Drug Chem Toxicol. 2014; 37(3): 276-280. 22. Alzoubi K, Khabour O, Hussain N, Al-Azzam S, Mhaidat M. Evaluation of vitamin B12 effects on DNA damage induced by pioglitazone. Mutat Res. 2012; 748(1-2): 48-51. 23. Alsatari ES, Azab M, Khabour OF, Alzoubi KH, Sadiq MF. Assessment of DNA damage using chromosomal aberrations assay in lymphocytes of waterpipe smokers. Int J Occup Med Environ Health. 2012; 25(3): 218-224. 24. Khabour OF, Alsatari ES, Azab M, Alzoubi KH, Sadiq MF. Assessment of genotoxicity of waterpipe and cigarette smoking in lymphocytes using the sister-chromatid exchange assay: A comparative study. Environ Mol Mutagen. 2011; 52(3): 224-228. 25. Alzoubi KH, Khabour OF, Jaber AG, Al-Azzam SI, Mhaidat NM, Masadeh MM. Tempol prevents geno-toxicity induced by vorinostat: role of oxidative DNA damage. Cytotechnology. 2014; 66(3): 449-455. 26. Khabour OF, Alzoubi KH, Mfady DS, Alasseiri M, Hasheesh TF. Tempol protects human lymphocytes from genotoxicity induced by cisplatin. Int J Clin Exp Med. 2014; 7(4): 982-988. 27. Al-Sweedan SA, Khabour O, Isam R. Genotoxicity assessment in patients with thalassemia minor. Mutat Res. 2012; 744(2): 167-171. 28. Kaya FF, Topaktas M. Genotoxic effects of potassium bromate on human peripheral lymphocytes in vitro. Mutat Res .2007; 626(1-2): 48-52. 29. M’Bemba-Meka P, Lemieux N, Chakrabarti SK. Role of oxidative stress and intracellular calcium in nickel carbonate hydroxide-induced sisterchromatid exchange, and alterations in replication index and mitotic index in cultured human peripheral blood lymphocytes. Arch Toxicol. 2007; 81(2): 89-99. 30. Rooney DE, Ed. Human Cytogenetics. A Practical Approach, 3rd ed., Vol. 2: Malignancy and Acquired Abnormalities. Oxford, UK: Oxford University Press, 2001. 31. Khabour OF, Saleh N, Alzoubi KH, Hisaindee S, Al-Fyad D, Al-Kaabi L, et al. Genotoxicity of structurally related copper and zinc containing Schiff base complexes. Drug Chem Toxicol. 2013; 36(4): 435-442. 32. Ivett JL, Tice RR. Average generation time: A new method of analysis and quantitation of cellular proliferation kinetics. Environ Mutagen. 1982; 4: 358-370. 33. Tsai KL, Chiu TH, Tsai MH, Chen HY, Ou HC. Vinorelbine-induced oxidative injury in human endothelial cells mediated by AMPK/PKC/ NADPH/NF-kappaB pathways. Cell Biochem Biophys. 2012; 62(3): 467-479. 34. Zhao J, Li H, Zhai Q, Qiu Y, Niu Y, Dai Y, et al. [Endonuclease modified comet assay for oxidative DNA damage induced by detection of genetic toxicants]. Zhonghua Yu Fang Yi Xue Za Zhi. 2014; 48(3): 208-212. 35. Madhu P, Reddy KP, Reddy PS. Melatonin reduces oxidative stress and restores mitochondrial function in the liver of rats exposed to chemotherapeutics. J Exp Zool A Ecol Genet Physiol. 2015; 323(5): 301-308. 36. Lee-Chen SF, Chen CL, Ho LY, Hsu PC, Chang JT, Sun CM, et al. Role of oxidative DNA damage in hydroxychavicol-induced genotoxicity. Mutagenesis. 1996; 11(5): 519-523. 37. Ogura H, Takeuchi T, Morimoto K. A comparison of the 8-hydroxydeoxyguanosine, chromosome aberrations and micronucleus techniques for the assessment of the genotoxicity of mercury compounds in human blood lymphocytes. Mutat Res. 1996; 340(2-3): 175-182. 38. Tari C, Fournier N, Briand C, Ducet G, Crevat A. Action of vinca alkaloides on calcium movements through mitochondrial membrane. Pharmacol Res Commun. 1986; 18(6): 519-528. 39. Sanchez P, Llorente MT, Castano A. Flow cytometric detection of micronuclei and cell cycle alterations in fish-derived cells after exposure to three model genotoxic agents: Mitomycin C, vincristine sulfate and benzo(a) pyrene. Mutat Res. 2000; 465(1-2): 113-122. 40. Le Fevre AC, Boitier E, Marchandeau JP, Sarasin A, Thybaud V. Characterization of DNA reactive and non-DNA reactive anticancer drugs by gene expression profiling. Mutat Res. 2007; 619(1-2): 16-29. 41. Geriyol P, Basavanneppa HP, Dhananjaya BL. Protecting effect of caffeine against vinblastine (an anticancer drug) induced genotoxicity in mice. Drug Chem Toxicol. 2015; 38(2): 188-195. 42. Wang YJ, Zhang LS. [Evaluation of the genotoxicity of vincristine and colchicine using mouse lymphoma tk mutation assay]. Wei Sheng Yan Jiu. 2006; 35(2): 179-181. 43. Choudhury RC, Das B, Misra S, Jagdale MB. Cytogenetic toxicity of vincristine. J Environ Pathol Toxicol Oncol. 2000; 19(4): 347-355. 44. Xing SG, Shi X, Wu ZL, Chen JK, Wallace W, Whong WZ, et al. Transplacental genotoxicity of triethyl-enemelamine, benzene, and vinblastine in mice. Teratog Carcinog Mutagen. 1992; 12(5): 223-230. 45. Novichkova EA, Onishchenko GE, Shtil AA. Microtubule depolymerization by vincristine causes cell death after transition from C mitosis to interphase. Dokl Biol Sci. 2003; 393: 575-578. 46. Horton JK, Houghton PJ, Houghton JA. Relationships between tumor responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumor xenografts. Biochem Pharmacol. 1988; 37(20): 3995-4000.



Number 26
Number 26 VOL. 26(2), 2023 All in one
Number 26
VOL. 26(2), 2023
Number 26
VOL. 26, 2023 Supplement
Number 26
VOL. 26(1), 2023
Number 25
VOL. 25(2), 2022
Number 25
VOL. 25 (1), 2022
Number 24
VOL. 24(2), 2021
Number 24
VOL. 24(1), 2021
Number 23
VOL. 23(2), 2020
Number 22
VOL. 22(2), 2019
Number 22
VOL. 22(1), 2019
Number 22
VOL. 22, 2019 Supplement
Number 21
VOL. 21(2), 2018
Number 21
VOL. 21 (1), 2018
Number 21
VOL. 21, 2018 Supplement
Number 20
VOL. 20 (2), 2017
Number 20
VOL. 20 (1), 2017
Number 19
VOL. 19 (2), 2016
Number 19
VOL. 19 (1), 2016
Number 18
VOL. 18 (2), 2015
Number 18
VOL. 18 (1), 2015
Number 17
VOL. 17 (2), 2014
Number 17
VOL. 17 (1), 2014
Number 16
VOL. 16 (2), 2013
Number 16
VOL. 16 (1), 2013
Number 15
VOL. 15 (2), 2012
Number 15
VOL. 15, 2012 Supplement
Number 15
Vol. 15 (1), 2012
Number 14
14 - Vol. 14 (2), 2011
Number 14
The 9th Balkan Congress of Medical Genetics
Number 14
14 - Vol. 14 (1), 2011
Number 13
Vol. 13 (2), 2010
Number 13
Vol.13 (1), 2010
Number 12
Vol.12 (2), 2009
Number 12
Vol.12 (1), 2009
Number 11
Vol.11 (2),2008
Number 11
Vol.11 (1),2008
Number 10
Vol.10 (2), 2007
Number 10
10 (1),2007
Number 9
1&2, 2006
Number 9
3&4, 2006
Number 8
1&2, 2005
Number 8
3&4, 2004
Number 7
1&2, 2004
Number 6
3&4, 2003
Number 6
1&2, 2003
Number 5
3&4, 2002
Number 5
1&2, 2002
Number 4
Vol.3 (4), 2000
Number 4
Vol.2 (4), 1999
Number 4
Vol.1 (4), 1998
Number 4
3&4, 2001
Number 4
1&2, 2001
Number 3
Vol.3 (3), 2000
Number 3
Vol.2 (3), 1999
Number 3
Vol.1 (3), 1998
Number 2
Vol.3(2), 2000
Number 2
Vol.1 (2), 1998
Number 2
Vol.2 (2), 1999
Number 1
Vol.3 (1), 2000
Number 1
Vol.2 (1), 1999
Number 1
Vol.1 (1), 1998

 

 


 About the journal ::: Editorial ::: Subscription ::: Information for authors ::: Contact
 Copyright © Balkan Journal of Medical Genetics 2006